UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 26, 2014

 

CELLCEUTIX CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada

  

000-52321

  

30-0565645

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

 

100 Cummings Center, Suite 151-B

Beverly, MA 01915

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (978) 236-8717

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On December 26, 2014, the Board of Directors of Cellceutix Corporation (the “Company”) approved bonus payments for the year 2014 to Leo Ehrlich, the Company’s Chief Executive Officer in the amount of $250,000, Dr. Krishna Menon, the Company’s President in the amount of $250,000, and Dr. James Alexander, the Company’s Chief Operations Officer was awarded 25,000 options exercisable for three years at $4.71 per common share.

 

 
2

  

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  CELLCEUTIX CORPORATION  
       
Dated: December 26, 2014 By: /s/ Leo Ehrlich  
    Leo Ehrlich  
   

Chief Executive Officer

  

 

 

 

3

Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Innovation Pharmaceuticals (PK) Charts.
Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Innovation Pharmaceuticals (PK) Charts.